Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02796677 · ClinicalTrials.gov registry record · Phase 3
AMPLIFY - D6571C00001 Duaklir USA Phase III Study
A Phase 3 study of Chronic Obstructive Pulmonary Disease, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,595
- Enrollment target
- 20
- Study locations
NCT02796677 is a Phase 3 study of Chronic Obstructive Pulmonary Disease that has completed, run by AstraZeneca. The registered enrollment target is 1,595 participants, roughly in line with the 1,735-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target. The trial reports 20 study locations across 5 states.
The verdict
NCT02796677, a Phase 3 study of Chronic Obstructive Pulmonary Disease, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,595 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered to patients with stable chronic obstructive pulmonary disease (COPD).
Conditions Studied
Interventions
- DRUG Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)
- DRUG Aclidinium bromide 400 μg (AB 400 μg)
- DRUG Formoterol fumarate 12 μg (FF 12 μg)
- OTHER Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg
- DRUG Tiotropium 18 μg (TIO 18 μg)
Study Locations (20)
Florida
- Research Site - Clearwater
- Research Site - Edgewater
- Research Site - Hollywood
- Research Site - Homestead
- Research Site - Miami
- Research Site - Miami
- Research Site - Miami Lakes
- Research Site - Ormond Beach
- Research Site - Port Orange
- Research Site - Sarasota
- Research Site - St. Petersburg
California
- Research Site - Corona
- Research Site - Fresno
- Research Site - Fullerton
- Research Site - Lincoln
- Research Site - San Diego
Arizona
- Research Site - Phoenix
- Research Site - Tucson
Alabama
- Research Site - Gulf Shores
Connecticut
- Research Site - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,595 participants |
| Start Date | 2016-07-05 |
| Est. Completion | 2017-06-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02796677
The ClinicalTrials.gov registry entry for NCT02796677 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,595 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 1,735-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 5 interventions - of which Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) is the first listed.
NCT02796677 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT02796677 about?
NCT02796677 is a clinical study titled "AMPLIFY - D6571C00001 Duaklir USA Phase III Study". This is a multiple dose, randomized, parallel, double-blind, double-dummy, multicenter and multinational Phase III study to determine the efficacy and safety of Aclidinium bromide 400μg/Formoterol Fumarate (AB/FF) 12 μg compared to individual components and TIO (Tiotropium) 18 μg when administered t...
What is the current status of trial NCT02796677?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,595 participants. The study started on 2016-07-05. Estimated completion is 2017-06-08.
What conditions does trial NCT02796677 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease.
What interventions are being tested in trial NCT02796677?
The interventions under investigation include: Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg) (DRUG), Aclidinium bromide 400 μg (AB 400 μg) (DRUG), Formoterol fumarate 12 μg (FF 12 μg) (DRUG), Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg (OTHER), Tiotropium 18 μg (TIO 18 μg) (DRUG).
Who is sponsoring clinical trial NCT02796677?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02796677 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
RECRUITING · Phase 3
-
A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
RECRUITING · Phase 3
-
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD
ACTIVE NOT RECRUITING · Phase 3
-
A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 3
-
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate to Severe COPD With Type 2 Inflammation
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.